Table 2.
- Summary of real-life studies supporting the safety and efficacy of anti-VEGFs.
| Study | Drugs | Study design | Patient status | Number (eyes) | Follow-up (months) | Mean number IVI | Baseline VA (letters) | Final VA (letters) | Mean VA gain (letters) | Mean CRT reduction | IOP | Cataract progression/extraction |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bahrami et al91 | Aflibercept | Prospective | Non-Naïve | 43 | 6 | 5 | 67.8 | 71 | 3.2 | 37 μm | 0% (IOP ≥25 mmHg or a rise of IOP ≥10 mmHg) | 0% |
| Kaiho et al92 | Aflibercept | ND | Non-Naïve | 51 | 12 | 3.8 | 65.5 | 70 | 4.5 | ND | ND | ND |
| Aksoy et al93 | Bevacizumab | Prospective | Naïve | 20 | 6 | 6 | 51 | 55.5 | 4.5 | 210 μm | 10% (IOP >21 mmHg) | 2.50% |
| Fong et al94 | Bevacizumab | Retrospective | Mixed (65% naive, 30% laser, 4% steroid) | 309 | 24 | 3.1 | 57 | 62.3 | 5.3 | ND | ND | ND |
| Güler et al95 | Bevacizumab | Prospective | ND | 20 | 9 | 6 | 38 | 42 | 4 | 295 ± 42 μm | ND | 0% |
| Koc et al96 | Bevacizumab | Retrospective | Naïve | 90 | 24 | 4.9 | 45.2 | 48.7 | 3.5 | 74.7 ± 133.9 | ND | 13.70% |
| Riazi-Esfahani et al97 | Bevacizumab | ND | Naïve | 46 | 6 | 67.5 | 72.5 | 5 | 102 ± 108 | 6.5% (IOP ≥21 mmHg) | 0 | |
| Cheema et al98 | Bevacizumab (diffuse) | Retrospective | ND | 28 | 6 | 1.3 | 44 | 45 | 1 | ND | ND | ND |
| Ciulla et al99 | Ranibizumab | Retrospective | Non-Naïve | 33 | 12 | 6 | 59 | 63 | 4 | 44 μm | ND | ND |
| Egan et al100 | Ranibizumab | Retrospective | Mixed (49.6% Naive) | 3103 | 24 | 5.4 | 51.1 | 52.5 | 1.4 | ND | ND | ND |
IVI: intravitreal injection, VA: visual acuity, CR: central retnal thickness, IOP: intra-ocular pressure, ND: not determined/detected